摘要
目的：低分子质量肝素为在心血管外科手术中应用更为安全可靠的抗凝药物，且给药方便，对凝血系统影响小，故收集有关文献资料，对其加以综述介绍。方法：根据文献报道的从标准肝素中分离出分子质量较小的肝素片段即低分子质量肝素，以其在心血管外科中替代标准肝素应用。结果：文献资料表明，低分子质量肝素与标准肝素相比，抗凝效果相同，但对凝血系统影响小，不易引起出血及血小板减少。结论：低分子质量肝素可以取代标准肝素在临床外科的应用。
关键词
标准肝素 /
低分子质量肝素 /
出血 /
血小板减少 /
抗凝剂
{{custom_keyword}} /
宋光民;宋惠民.
低分子质量肝素在心血管外科的应用[J]. 中国药学杂志, 1998, 33(02): 72-75
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Green D，Hirsh J，Heit J，et al．Low molecular weight heparin：A critical analysis of clinical trials．Pharmacol Rev，1994，46(1)：90．
2 Brace LD，Fareed J．Heparin-induced Platelet aggregation Ⅱ．dose/response relationships for two low molecular weight heparin fractions．Thromb Res，1990，59(1)：1．
3 Aster RH．Heparin-Induced thrombocytopenia and thrombosis．N Eng J Med，1995，332(20)：1374．
4 Kelton JG，Hirsh J．Bleeding associated with antithrombotic therapy．Semin Hematol，1980，17(4)：259．
5 Pifarre R，Babka R，Sullivan HJ，et al．Management of postoperative heparin rebound following cardiopulmonary bypass．J Thorac Cardiovasc Surg，1981，81(3)：378．
6 Henny CHP，Ten Cate H，Ten Cate J·W，et al．A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs．J Lab Clin Med，1985，106(2)：187．
7 Meuleman DG，Hobbelen PML，Dedem GV．et al．A novel antithmmbotie heparinoid (ORGl0172) devoid of bleeding inducing capacity：A survey of its pharmacological properities in experimental animal models．Thromb Res．1982，27(3)：353．
8 Gouault-Heilmann M，Huet Y，Conlant G，et al．Cardiopulmonary bypass with a low molecular weight heparin fraction．Lancet，1983，2(8363)：1374．
9 Blackshear JL，Callgahn WG，Califf RM．Medical approaches to prevention of restenosis after coronary angioplasty．J Am Coll Cardiol．1987，9(4)：834．
10 Currier JW，Pow TK，Hauderschild CC，et al，Low molecular weight heparin (Enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemie rabbit．J Am Coll Cardiol，1991，17(6 Suppl B)：118B．
11 Yilmaz S．Paavonen T，Hayry P．Chronic rejection of rat renal allografts Transplantation，1992，53(4)：823．
12 Wanders A．Akyurek ML，Waltenberger J，et al．Ischemia induced transplant arteriosclerosis in the rat．Arterioscter Thromb Vasc Biol．1995，15(1)：145．
13 Akyurek ML，Wanders A，Aurivillius M，et al．Effects of angiopeptin on transplant arteriosclerosis in the rat Transplant Int，1995，8(2)：103．
14 Libby P，Tanaka H．The Pathogenes of coronary arteriosclerosis (“chronicrejection”) in transplanted hearts．Clin Transplant，1994，8(3 pt 2)：313．
15 Rubin K，Tingstrom A，Hansson GK，Ronnstrand L．et al．Induction of Btype receptors for platelet-derived growth factor ln vascular inflammation：possible implications for development of vascular proliferative lesions．Lancet，1988，1(8599)：1353．
16 Sakuda H，Nakoshima Y，Kuriyama S，et al．Media conditioned by smooth muscle cells cultured ln a variety of hypoxic environments stimulates in vitro angiogenesis．A relationship to transforming growth factor-β l．Am J Pathlo，1992，141(6)：1507．
17 Russell R，Glomset J，Kariya B，et al．A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro．Proc Nati Acad Sci USA．1974，71(4)：1207．
18 Levent MA，Keiko F，Alkwin W．Et al Inhibition of transplant arteriosclerosis in rat aortic grafts by low molecular weight heparin derivatives．Transplantation，1995．59(11)：1517．
19 FelIstrom BC．Larsson E．Pathogenesis and treatment perspectives of chronic graft rejection (CVR)．Immunol Rev，1993，134：83．
20 Berk BC，Gordon JB，Alexander RW．Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty．
J Am Coll Cardiol，1991，17(6 8upplB)：111B．
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
